Journal: Frontiers in Immunology

Article Title: Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

doi: 10.3389/fimmu.2022.816159

Figure Lengend Snippet: Optimization and control parameters of the neutralisation assay performance. (A) SARS-CoV-2 working stock titre determined in assay runs using Vero E6 cells from different subcultivations. (B) SARS-CoV-2 working stock stability during the storage at -60°C or below. (C) Stability of anti-SARS-CoV-2 in-house standard during 6-month storage. The break in line indicates the start of two times lower dilution of SARS-CoV-2 working stock usage as a challenge virus, due to the drop of its infectivity.

Article Snippet: After the international standard became available, Biomerieux calibrated VIDAS SARS-CoV-2 IgG accordingly to it and their previous cut off value of 1.0 was replaced with 20 IU mL -1 .

Techniques: Infection

Journal: Frontiers in Immunology

Article Title: Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

doi: 10.3389/fimmu.2022.816159

Figure Lengend Snippet: The role of complement in SARS-CoV-2 neutralisation. (A) Decrease of SARS-CoV-2 neutralisation power of convalescent sera upon heat inactivation; * p <0.0001 ( n =69) according to the two-tailed t -test for paired samples; ( t =12.809; DF=68), (B) Factor of neutralisation titre decrease in relation to the quantity of neutralising antibodies in the convalescents’ sera.

Article Snippet: After the international standard became available, Biomerieux calibrated VIDAS SARS-CoV-2 IgG accordingly to it and their previous cut off value of 1.0 was replaced with 20 IU mL -1 .

Techniques: Two Tailed Test

Journal: Frontiers in Immunology

Article Title: Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

doi: 10.3389/fimmu.2022.816159

Figure Lengend Snippet: Persistence of anti-SARS-CoV-2 neutralizing antibodies in convalescent sera. (A) Neutralisation titre in convalescent donors’ sera ( n =113) in relation to the time period between the illness and serum collection. (B) Longitudinal monitoring of neutralisation titre in sera of six convalescents.

Article Snippet: After the international standard became available, Biomerieux calibrated VIDAS SARS-CoV-2 IgG accordingly to it and their previous cut off value of 1.0 was replaced with 20 IU mL -1 .

Techniques:

Journal: Frontiers in Immunology

Article Title: Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

doi: 10.3389/fimmu.2022.816159

Figure Lengend Snippet: SARS-CoV-2 neutralisation titre in convalescent donors’ sera in relation to disease severity according to scale: 0 – no symptoms, 1 – mild, 2 – moderate, 3 – severe; * p < 0.002 in comparison to other groups, calculated by Kruskal-Wallis test.

Article Snippet: After the international standard became available, Biomerieux calibrated VIDAS SARS-CoV-2 IgG accordingly to it and their previous cut off value of 1.0 was replaced with 20 IU mL -1 .

Techniques:

Journal: Frontiers in Immunology

Article Title: Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

doi: 10.3389/fimmu.2022.816159

Figure Lengend Snippet: Neutralising SARS-CoV-2 antibody titres (in IU mL -1 ) during COVID-19 convalescent plasma therapy in the first (A) , second (B) and the third (C) representative COVID-19 patient, all three completely lacking their own immunoglobulins due to the underlying haematological malignancy and its treatment. The quantities of measured NAbs were above the lowest NT detected in successfully recovered persons.

Article Snippet: After the international standard became available, Biomerieux calibrated VIDAS SARS-CoV-2 IgG accordingly to it and their previous cut off value of 1.0 was replaced with 20 IU mL -1 .

Techniques:

Journal: Eurosurveillance

Article Title: External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021

doi: 10.2807/1560-7917.ES.2022.27.42.2101057

Figure Lengend Snippet: Performance of different SARS-CoV-2 assays that were used by three or more laboratories, external quality assessment, EU/EEA, February–April 2021 (n = 18)

Article Snippet: Four qualitative assays in this EQA had been previously used to characterise the JRC standards as positive, both EURM-017 [ ] and EURM-018 [ ]: Genscript (cPass SARS-CoV-2 Neutralisation Antibody detection kit), Roche (Elecsys Anti-SARS-CoV-2), Abbott (SARS-CoV-2 IgG) and Abbott (SARS-CoV-2 IgM).

Techniques: Enzyme-linked Immunosorbent Assay, Inhibition, Virus

Journal: PLoS ONE

Article Title: Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity

doi: 10.1371/journal.pone.0253889

Figure Lengend Snippet: Information on three chemiluminescence immunoassay used for testing antibody of COVID-19.

Article Snippet: SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).

Techniques: Chemiluminescence Immunoassay, Clinical Proteomics

Journal: PLoS ONE

Article Title: Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity

doi: 10.1371/journal.pone.0253889

Figure Lengend Snippet: Demographic laboratory characteristics of patients on admission.

Article Snippet: SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).

Techniques: Cell Counting

Journal: PLoS ONE

Article Title: Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity

doi: 10.1371/journal.pone.0253889

Figure Lengend Snippet: Distribution of the SARS-CoV-2 antibody S/CO index measured by three chemiluminescence immunoassays according to days after onset.

Article Snippet: SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).

Techniques:

Journal: PLoS ONE

Article Title: Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity

doi: 10.1371/journal.pone.0253889

Figure Lengend Snippet: Patients showed discrepancy in SARS-CoV-2 antibody positivity in three automated immunoassay system.

Article Snippet: SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).

Techniques:

Journal: PLoS ONE

Article Title: Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity

doi: 10.1371/journal.pone.0253889

Figure Lengend Snippet: Pairwise association between clinical biomarkers indicating disease severity and SARS-CoV-2 antibody index.

Article Snippet: SARS-CoV-2 antibody index was measured using SARS-CoV2 IgG reagent from Alinity (Abbott) and Access (Beckman Coulter) and SARS-CoV2 Total (IgG + IgM) from Atellica (Siemens).

Techniques: Clinical Proteomics